294 related articles for article (PubMed ID: 30967527)
21. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
22. Long noncoding RNA myocardial infarction-associated transcript regulated the pancreatic stellate cell activation to promote the fibrosis process of chronic pancreatitis.
Liu H; Yu K; Ma P; Xiong L; Wang M; Wang W
J Cell Biochem; 2019 Jun; 120(6):9547-9555. PubMed ID: 30582203
[TBL] [Abstract][Full Text] [Related]
23. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
24. LncRNA MIAT overexpression reduced neuron apoptosis in a neonatal rat model of hypoxic-ischemic injury through miR-211/GDNF.
Li EY; Zhao PJ; Jian J; Yin BQ; Sun ZY; Xu CX; Tang YC; Wu H
Cell Cycle; 2019 Jan; 18(2):156-166. PubMed ID: 30563429
[TBL] [Abstract][Full Text] [Related]
25. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
26. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
Yoshida T; Ri M; Kinoshita S; Narita T; Totani H; Ashour R; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
PLoS One; 2018; 13(5):e0196780. PubMed ID: 29738534
[TBL] [Abstract][Full Text] [Related]
27. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.
Liu Y; Cheng P; Zhao W; Zhu L; Sui J; Dai Y; Lai Y
Leuk Res; 2022 Mar; 114():106785. PubMed ID: 35074616
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenomics and chemical library screens reveal a novel SCF
Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
[TBL] [Abstract][Full Text] [Related]
29. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
30. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
31. Role of Apg-1 in HSF1 activation and bortezomib sensitivity in myeloma cells.
Zhu M; Huang Y; Tang J; Shao S; Zhang L; Zhou Y; He S; Wang Y
Exp Hematol; 2020 Jan; 81():50-59. PubMed ID: 31899217
[TBL] [Abstract][Full Text] [Related]
32. Downregulated lncRNA-MIAT confers protection against erectile dysfunction by downregulating lipoprotein lipase via activation of miR-328a-5p in diabetic rats.
Huo W; Hou Y; Li Y; Li H
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1226-1240. PubMed ID: 30660685
[TBL] [Abstract][Full Text] [Related]
33. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
[No Abstract] [Full Text] [Related]
34. Bortezomib inhibited the progression of diffuse large B-cell lymphoma via targeting miR-198.
Wang R; Shen J; Wang Q; Zhang M
Biomed Pharmacother; 2018 Dec; 108():43-49. PubMed ID: 30216798
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
36. Effect of lncRNA-MIAT on kidney injury in sepsis rats via regulating miR-29a expression.
Zhang Y; Zhang YY; Xia F; Yang AX; Qian JX; Zhao H; Tao WY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10942-10949. PubMed ID: 31858562
[TBL] [Abstract][Full Text] [Related]
37. Long Non-Coding RNA of Myocardial Infarction Associated Transcript (LncRNA-MIAT) Promotes Diabetic Retinopathy by Upregulating Transforming Growth Factor-β1 (TGF-β1) Signaling.
Li Q; Pang L; Yang W; Liu X; Su G; Dong Y
Med Sci Monit; 2018 Dec; 24():9497-9503. PubMed ID: 30595603
[TBL] [Abstract][Full Text] [Related]
38. The interaction of long non-coding RNA MIAT and miR-133 play a role in the proliferation and metastasis of pancreatic carcinoma.
Li TF; Liu J; Fu SJ
Biomed Pharmacother; 2018 Aug; 104():145-150. PubMed ID: 29772434
[TBL] [Abstract][Full Text] [Related]
39. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Amodio N; Di Martino MT; Foresta U; Leone E; Lionetti M; Leotta M; Gullà AM; Pitari MR; Conforti F; Rossi M; Agosti V; Fulciniti M; Misso G; Morabito F; Ferrarini M; Neri A; Caraglia M; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Cell Death Dis; 2012 Nov; 3(11):e436. PubMed ID: 23190608
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA PTTG3P functions as an oncogene by sponging miR-383 and up-regulating CCND1 and PARP2 in hepatocellular carcinoma.
Zhou Q; Zhang W; Wang Z; Liu S
BMC Cancer; 2019 Jul; 19(1):731. PubMed ID: 31340767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
